- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Common Acute Lymphoblastic Leukemia Antigen.
Displaying page 1 of 1.
EudraCT Number: 2022-001101-52 | Sponsor Protocol Number: CART19-BE-03Ped | Start Date*: 2022-11-07 | |||||||||||
Sponsor Name:Fundació Privada per a la Recerca i la Docència Sant Joan de Déu | |||||||||||||
Full Title: Phase 2 study of the infusion of autologous, differentiated, peripheral blood T-cells expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3... | |||||||||||||
Medical condition: CD19+ acute lymphoid leukemia resistant or refractory to treatment | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002972-29 | Sponsor Protocol Number: CART19-BE-01 | Start Date*: 2017-05-16 | ||||||||||||||||||||||||||
Sponsor Name:IDIBAPS | ||||||||||||||||||||||||||||
Full Title: Pilot study on the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (... | ||||||||||||||||||||||||||||
Medical condition: Patients with leukemia or lymphoma refractory to therapy | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000827-94 | Sponsor Protocol Number: U-DANCE-anti-AML | Start Date*: 2016-09-08 | ||||||||||||||||
Sponsor Name:UMC Utrecht | ||||||||||||||||||
Full Title: A phase I/II post cord blood HCT dendritic cells vaccination trial directed against WT1 for pediatric acute myeloid leukemia: the U-DANCE-anti-AML trial | ||||||||||||||||||
Medical condition: AML: Acute Myeloid leukemia/ cancer of blood and bone marrow | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Not Authorised) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007612-29 | Sponsor Protocol Number: UCL/09/0050 | Start Date*: 2013-02-26 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Immunotherapy with CD19ζ chimeric antigen receptor gene-modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia | |||||||||||||
Medical condition: The medical condition under investigation is childhood precursor B acute lymphoblastic leukaemia (ALL). | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003604-39 | Sponsor Protocol Number: MC-FludT.17/M | Start Date*: 2014-04-11 | ||||||||||||||||||||||||||
Sponsor Name:medac GmbH | ||||||||||||||||||||||||||||
Full Title: Clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haemato... | ||||||||||||||||||||||||||||
Medical condition: Male and female children with haematologic malignant diseases as acute lymphoblastic leukaemias (ALL), acute myeloid leukaemias (AML), myelodysplastic syndromes (MDS) and juvenile myelomonocytic le... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) PL (Completed) AT (Completed) CZ (Completed) GB (Completed) IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002549-39 | Sponsor Protocol Number: Ponatinib-1501 | Start Date*: 2020-12-07 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lympho... | |||||||||||||
Medical condition: acute lymphoblastic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) CZ (Completed) NL (Ongoing) IT (Ongoing) PL (Completed) PT (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005010-30 | Sponsor Protocol Number: KTE-C19-104 | Start Date*: 2017-09-27 | |||||||||||
Sponsor Name:Kite Pharma, Inc. | |||||||||||||
Full Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4) | |||||||||||||
Medical condition: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) DE (Ongoing) FR (Ongoing) CZ (Ongoing) SE (Restarted) BE (Ongoing) PL (Temporarily Halted) IT (Restarted) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005066-30 | Sponsor Protocol Number: RG_14-088 | Start Date*: 2018-03-20 | |||||||||||
Sponsor Name:The University of Birmingham | |||||||||||||
Full Title: MyeChild 01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with ... | |||||||||||||
Medical condition: Newly diagnosed acute myeloid leukaemia (AML), high risk myelodysplastic syndrome(MDS) and isolated myeloid sarcoma (either de novo or secondary) are eligible for the trial. | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Ongoing) GB (GB - no longer in EU/EEA) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002333-42 | Sponsor Protocol Number: OC-01-21001 | Start Date*: 2022-11-25 | |||||||||||
Sponsor Name:OneChain Immunotherapeutics | |||||||||||||
Full Title: Safety and efficacy of hCD1a-CAR T (OC-1) therapy, in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) | |||||||||||||
Medical condition: Children older than 2 years or adults, male and female, with refractory or relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma (T-ALL/LL). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003907-20 | Sponsor Protocol Number: C16051 | Start Date*: 2019-07-10 | ||||||||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limit | ||||||||||||||||||
Full Title: Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refract... | ||||||||||||||||||
Medical condition: Relapsed or Refractory Acute Lymphoblastic Leukemia and Relapsed or Refractory Lymphoblastic Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001246-34 | Sponsor Protocol Number: JCAR017-BCM-004 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||
Full Title: A phase 1 / 2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory B-ALL and B-NHL (TRANSCEND PEDALL) | ||||||||||||||||||||||||||||
Medical condition: Relapsed or refractory (r/r) CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL). | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Ongoing) DE (Prematurely Ended) ES (Prematurely Ended) IT (Restarted) BE (Completed) NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004134-42 | Sponsor Protocol Number: SLSG18-301 | Start Date*: 2020-09-22 | |||||||||||
Sponsor Name:Sellas Life Sciences | |||||||||||||
Full Title: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid ... | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) ES (Ongoing) GR (Ongoing) HU (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001706-42 | Sponsor Protocol Number: JCAR015-ALL-001 | Start Date*: 2016-11-16 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 2, Open-Label, Multiple Cohort, Single-Arm, Multi-Center Trial To Determine The Safety, Feasibility, And Efficacy Of JCAR015 In Adult Subjects With B-Cell Acute Lymphoblastic Leukemia | |||||||||||||
Medical condition: B-cell Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004808-60 | Sponsor Protocol Number: HD-CAR-1/V04 | Start Date*: 2018-04-12 | ||||||||||||||||
Sponsor Name:University Hospital Heidelberg | ||||||||||||||||||
Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial | ||||||||||||||||||
Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.